Q2 2024

Filed Aug 8, 2024 · 10-Q · 39 days after period end · 0000950170-24-094109

Q2 2024 · 10-Q

Revenue

$0.00

no prior Q2 2023 on file

Net Income

-$57.92M

N/M vs Q2 2023

EPS Diluted

-$0.75

N/M vs Q2 2023

Operating Income-$69,104,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	$0.00	—	$536.00K	$2.22M
Net Income	-$57.92M	-$47.46M	-$31.16M	-$22.11M
EPS Diluted	-$0.75	-$0.72	-$0.55	-$0.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR